GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
61.18
+0.31 (0.51%)
At close: Feb 18, 2026, 4:00 PM EST
61.45
+0.27 (0.44%)
After-hours: Feb 18, 2026, 7:21 PM EST
Revenue
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
|---|
| 7.69B | 7.09B | | | | | | | | | | | | |
| 8.44% | 10.01% | | | | | | | | | | | | |
Respiratory, Immunology and Inflammation Revenue | 3.81B | 3.30B | | | | | | | | | | | | |
Respiratory, Immunology and Inflammation Revenue Growth | 15.49% | 9.06% | | | | | | | | | | | | |
| 1.98B | 1.41B | | | | | | | | | | | | |
| 40.21% | 92.89% | | | | | | | | | | | | |
Specialty Medicines Revenue | 13.47B | 11.81B | | | | | | | | | | | | |
Specialty Medicines Revenue Growth | 14.09% | 15.29% | | | | | | | | | | | | |
| 3.56B | 3.36B | | | | | | | | | | | | |
| 5.77% | -2.38% | | | | | | | | | | | | |
| 1.58B | 1.44B | | | | | | | | | | | | |
Meningitis Revenue Growth | 10.16% | 14.05% | | | | | | | | | | | | |
| 303.00M | 408.00M | | | | | | | | | | | | |
| -25.74% | -19.05% | | | | | | | | | | | | |
Established Vaccines Revenue | 3.12B | 3.34B | | | | | | | | | | | | |
Established Vaccines Revenue Growth | -6.56% | 2.23% | | | | | | | | | | | | |
| 9.16B | 9.14B | | | | | | | | | | | | |
| 0.21% | -7.36% | | | | | | | | | | | | |
| 7.07B | 7.21B | | | | | | | | | | | | |
Respiratory Revenue Growth | -2.01% | 5.68% | | | | | | | | | | | | |
Other General Medicines Revenue | 2.97B | 3.22B | | | | | | | | | | | | |
Other General Medicines Revenue Growth | -7.68% | -5.30% | | | | | | | | | | | | |
General Medicines Revenue | 10.04B | 10.43B | | | | | | | | | | | | |
General Medicines Revenue Growth | -3.76% | 2.04% | | | | | | | | | | | | |
Total Commerical Operations Revenue | 32.67B | 31.38B | | | | | | | | | | | | |
Total Commerical Operations Revenue Growth | 4.12% | 3.46% | | | | | | | | | | | | |
| 32.67B | 31.38B | | | | | | | | | | | | |
| 4.12% | 3.46% | | | | | | | | | | | | |
Revenue by Geography
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
|---|
| 16.86B | 16.38B | | | | | | | | | | | | |
| 2.90% | 3.56% | | | | | | | | | | | | |
| 7.53B | 6.67B | | | | | | | | | | | | |
| 13.01% | 1.55% | | | | | | | | | | | | |
| 8.28B | 8.33B | | | | | | | | | | | | |
International Revenue Growth | -0.61% | 4.81% | | | | | | | | | | | | |
| 32.67B | 31.38B | | | | | | | | | | | | |
| 4.12% | 3.46% | | | | | | | | | | | | |
EBIT
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
|---|
Commercial Operations Segment Profit | 16.26B | 15.34B | | | | | | | | | | | | |
Commercial Operations Segment Profit Growth | 6.03% | 4.63% | | | | | | | | | | | | |
Research & Development Segment Profit | -6.25B | -5.85B | | | | | | | | | | | | |
| -2.08B | -5.47B | | | | | | | | | | | | |
| 7.93B | 4.02B | | | | | | | | | | | | |
Operating Income (Total) Growth | 97.26% | -40.38% | | | | | | | | | | | | |
Updated Feb 4, 2026. Data Source:
Fiscal.ai.